文献速递重症综合管理与镇静镇痛

COVID-19大流行期间行政审批时间差异:重症医学会Discovery网络病毒感染与呼吸系统疾病通用研究COVID-19登记处的横断面研究

Variations in Administrative Approvals During the COVID-19 Pandemic at Participating Sites in the Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study: COVID-19 Registry: A Cross-Sectional Study.
PubMed 文献 · Crit Care Explor · 2022-12-16
一句话结论在287个中心的VIRUS COVID-19登记处中,188个中心从伦理审查机构提交到首例患者数据录入的中位时间为28天,美国与非美国中心差异不显著。

该研究对参与病毒感染与呼吸系统疾病通用研究(VIRUS):全球COVID-19登记处的188名研究者进行问卷调查分析,评估各中心行政审批各阶段时长。从伦理审查机构提交到首例患者数据录入的中位时间为28天(四分位距16-50天),按国家(美国30天[17-50] vs 非美国23天[8-46],p=0.08)或既往多中心试验经验(有经验27天[15-51] vs 无经验29天[13-47],p=0.67)均无显著差异。美国中心女性主要研究者比例更高(50% vs 21%,p=0.002)。非美国中心在获得REDCap访问权限后至首例患者数据录入的时间显著更短(3天[1-6] vs 7天[1-28],p=0.02)。

要点

  • 188个中心从伦理审查机构提交到首例患者数据录入的中位时间为28天(四分位距16-50天)。
  • 美国中心该时间为30天(17-50),非美国中心为23天(8-46),差异无统计学意义(p=0.08)。
  • 有既往多中心试验经验的中心为27天(15-51),无经验中心为29天(13-47),差异无统计学意义(p=0.67)。
  • 非美国中心在获得REDCap访问权限后至首例数据录入的时间为3天(1-6),显著短于美国中心的7天(1-28)(p=0.02)。
  • 美国中心女性主要研究者比例为50%(n=77),高于非美国中心的21%(n=7)(p=0.002)。

适用人群与场景

  • 参与VIRUS:COVID-19登记处的188名研究者所在中心,该登记处为前瞻性、观察性全球登记数据库,共287个中心。
  • 截至2020年12月8日获得研究批准的各研究中心。

研究设计与关键结果

  • 研究类型为横断面调查分析,共287个中心中188个中心(美国155个,非美国33个)提供了完整的行政数据。
  • 从伦理审查机构提交到首例患者数据录入的中位时间为28天(四分位距16-50天)。
  • 按国家比较:美国中心30天(17-50) vs 非美国中心23天(8-46),差异无统计学意义(p=0.08)。
  • 按既往多中心试验经验比较:有经验中心27天(15-51) vs 无经验中心29天(13-47),差异无统计学意义(p=0.67)。
  • 美国中心女性主要研究者比例为50%(n=77),非美国中心为21%(n=7),差异有统计学意义(p=0.002)。
  • 非美国中心在获得REDCap访问权限后至首例患者数据录入的时间为3天(1-6),显著短于美国中心的7天(1-28)(p=0.02)。

证据类型、等级与局限

  • 证据类型:横断面调查分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在COVID-19大流行期间,各中心从伦理审查机构提交到首例患者数据录入的时间存在相当大的变异性,但按国家或既往多中心试验经验均无显著差异。
  • 作者认为,美国与非美国中心在获得REDCap访问权限后至首例数据录入的时间上存在显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: There is a paucity of literature regarding administrative approvals required for clinical studies during a pandemic. We aimed to evaluate variation in duration of administrative approvals within the Viral Infection and Respiratory illness Universal Study (VIRUS): A Global COVID-19 Registry.

DESIGN SETTING AND SUBJECTS: Survey analysis of 188 investigators who participated in the VIRUS: COVID-19 registry, a prospective, observational global registry database of 287 sites.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: For each study site approved through December 8, 2020, we assessed the duration in days: 1) from institutional review board (IRB) submission to IRB approval, 2) from IRB approval to Research Electronic Data Capture (REDCap) access, 3) from REDCap access to first patient data entry in REDCap, and 4) total duration from IRB submission to first patient data entry in REDCap. Analysis of variance and Wilcoxon rank-sum test were used to compare time durations. Of 287 sites, 188 sites (United States = 155, non-United States = 33) provided complete administrative data. There was considerable variability in duration from IRB submission to first patient data entry with median (interquartile range) of 28 days (16-50 d), with differences not significantly different by country (United States: 30 [17-50] vs non-United States: 23 d [8-46 d]; p = 0.08) or previous "multisite trial experience" (experienced: 27 [15-51] vs not experienced: 29 d [13-47 d]; p = 0.67). The U.S. sites had a higher proportion of female principal investigators (n = 77; 50%), compared with non-U.S. sites (n = 7; 21%; p = 0.002). Non-U.S. sites had a significantly shorter time to first patient data entry after REDCap access: 7 (1-28) versus 3 days (1-6 d) (p = 0.02).

CONCLUSIONS: In this Society of Critical Care Medicine global VIRUS: COVID-19 Registry, we identified considerable variability in time from IRB submission to first patient data entry with no significant differences by country or prior multicenter trial experience. However, there was a significant difference between US and non-U.S. sites in the time from REDCap access to first data entry.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Bansal V, Sharma M, Deo N, et al. Variations in Administrative Approvals During the COVID-19 Pandemic at Participating Sites in the Society of Critical Care Medicine Discovery Network Viral Infection and Respiratory Illness Universal Study: COVID-19 Registry: A Cross-Sectional Study. Crit Care Explor. 2022. PMID: 36567789. doi:10.1097/CCE.0000000000000822

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。